Active Complement Component 1, Q Subcomponent A (C1qA) Homo sapiens (Human) Active protein

Complement Component 1,q Subcomponent,Alpha Polypeptide

Add to Cart Distributors
Overview
Properties
  • Buffer Formulation20mM Tris, 150mM NaCl, pH8.0, containing 1mM EDTA, 1mM DTT, 0.01% SKL, 5% Trehalose and Proclin300.
  • Traits Freeze-dried powder, Purity > 95%
  • Isoelectric Point9.6
Share your citation Upload your experimental result Review Leave a message
Loading...

Share a new citation as an author

Upload your experimental result

Review

Please attach serial No. on instruction manual

Contact us

Please fill in the blank.

Name*
Organization
Address
E-mail address*
Telephone
Inquiry*
Verification code* CheckCode
  • Active Complement Component 1, Q Subcomponent A (C1qA) Packages (Simulation)
  • Active Complement Component 1, Q Subcomponent A (C1qA) Packages (Simulation)
  • Active Complement Component 1, Q Subcomponent A (C1qA) Figure . Gene Sequencing (extract)
  • APD207Hu01.png Figure. SDS-PAGE
  • Active Complement Component 1, Q Subcomponent A (C1qA) Figure. Western Blot
  • Certificate ISO9001: 2008, ISO13485: 2003 Registered

Activity test

Figure. The binding activity of C1qA with CRP.
The complement component 1q (C1q) is composed of 18 polypeptide chains: six A-chains, six B-chains, and six C-chains. Complement Component 1, Q Subcomponent A (C1qA) is six A-chains of C1q. Complement component 1q (C1q is a protein complex involved in the complement system, which is part of the innate immune system. C1q together with C1r and C1s form the C1 complex. It is potentially multivalent for attachment to the complement fixation sites of immunoglobulin. The sites are on the CH2 domain of IgG and, it is thought, on the CH4 domain of IgM. IgG4 cannot bind C1q, but the other three IgG types can. Besides, C Reactive Protein (CRP) has been identified as an interactor of C1qA, thus a binding ELISA assay was conducted to detect the interaction of recombinant human C1qA and recombinant human CRP. Briefly, C1qA were diluted serially in PBS, with 0.01% BSA (pH 7.4). Duplicate samples of 100μL were then transferred to CRP-coated microtiter wells and incubated for 2h at 37℃. Wells were washed with PBST and incubated for 1h with anti-C1qA pAb, then aspirated and washed 3 times. After incubation with HRP labelled secondary antibody, wells were aspirated and washed 3 times. With the addition of substrate solution, wells were incubated 15-25 minutes at 37℃. Finally, add 50µL stop solution to the wells and read at 450nm immediately. The binding activity of C1qA and CRP was shown in Figure 1, and this effect was in a dose dependent manner.

Usage

Reconstitute in 20mM Tris, 150mM NaCl (pH8.0) to a concentration of 0.1-1.0 mg/mL. Do not vortex.

Storage

Avoid repeated freeze/thaw cycles. Store at 2-8°C for one month. Aliquot and store at -80°C for 12 months.

Stability

The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37°C for 48h, and no obvious degradation and precipitation were observed. The loss rate is less than 5% within the expiration date under appropriate storage condition.

Citations

  • LCN2 is a new diagnostic biomarker and potential therapeutic target in idiopathic short staturePubmed:35610759
  • Competitive inhibition of the classical complement pathway using exogenous single-chain C1q recognition proteinsPubmed:35690144

Recommend products